ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KERX Keryx Biopharmaceuticals, Inc. (delisted)

3.36
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Keryx Biopharmaceuticals, Inc. (delisted) NASDAQ:KERX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.36 3.10 3.35 0 01:00:00

Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 36th Annual Healthcare Conference on January 10, 2018...

22/12/2017 2:05pm

GlobeNewswire Inc.


Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.

Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast its corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2018 at 11:30 a.m. PST (2:30 p.m. EST). In addition, the company will webcast the question & answer session immediately following its presentation at 12:00 p.m. PST (3:00 p.m. EST).

A live audio webcast of both the presentation and breakout session will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” Archived versions of the webcasts will be available for at least 15 days following the conclusion of each session.

About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of more than 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets.

KERYX BIOPHARMACEUTICALS CONTACT:Lora PikeSenior Director, Investor Relations & Corporate CommunicationsT: 617-466-3511lora.pike@keryx.com

1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart

Your Recent History

Delayed Upgrade Clock